Company Directory

Targeting developmentally-silent oncogenic drivers for cancer therapy

Awen Oncology is a Welsh oncology biotechnology company developing first-in-class therapeutics that target cancer-specific proteins derived from developmental genes that are dormant in healthy adult tissue but aberrantly reactivated in tumour cells. The company's platform integrates high-throughput cell and molecular biology with computational medicinal chemistry to identify and progress novel inhibitors across multiple cancer types, including rare malignancies with no current treatment options.

Automated chiral chemistry platform for small molecule drug discovery

LCC Technologies is a drug discovery company providing biopharma partners with access to its platform, which combines a proprietary billion-scale virtual chiral library with AI-driven design and automated high-throughput synthesis. The platform delivers stereodefined, sp3-rich building blocks and drug-like compounds across target classes including kinases, GPCRs, and deubiquitinases. LCC operates as the UK arm of XtalPi, a global AI and robotics-driven R&D platform.

Structural chemistry database and software for drug discovery

The Cambridge Crystallographic Data Centre (CCDC) is a non-profit organisation that curates and distributes the Cambridge Structural Database (CSD), the world's repository of experimentally determined small-molecule organic and metal-organic crystal structures, containing over one million entries. Alongside the database, CCDC develops and licenses a suite of cheminformatics software tools used in pharmaceutical drug discovery, solid form analysis, and molecular design. The organisation also conducts independent research in structural chemistry and offers consultancy services to industrial clients.

AI-driven automated flow chemistry platform for chemical process development

SOLVE Chemistry is a contract research and technology company providing AI-powered process development services to pharmaceutical, agrochemical, and specialty chemical manufacturers. Its automated flow chemistry laboratory collects dense kinetic datasets on chemical reactions at speed, training proprietary machine learning and micro-kinetic models that predict optimal manufacturing conditions. Clients receive quantitative, FAIR-compliant data and model outputs via API, enabling faster and more sustainable process scale-up.

Cloud-based informatics platform for drug discovery data management

Collaborative Drug Discovery (CDD) is a software company providing a cloud-based informatics platform for drug discovery research. Its flagship product enables scientists to register compounds, manage bioassay and chemical data, track inventory and capture experiments through an integrated electronic laboratory notebook. The platform supports secure data sharing across distributed teams and external collaborators. CDD Vault is used by pharmaceutical, biotechnology and academic research organisations working across small molecule drug discovery.

Integrated outsourced drug discovery and development platform

RxCelerate is a contract research organisation providing fully integrated drug discovery and development services to pharmaceutical and biotech companies. Based at Babraham Research Campus, the company offers end-to-end programme delivery spanning computational design, antibody discovery, medicinal chemistry, in vitro and in vivo pharmacology, GLP bioanalysis and preclinical development. Its model targets virtual and semi-virtual biotechs requiring turnkey outsourcing. RxCelerate employs over 100 scientists and also has offices in Boston.

AI platform engineering molecular glue drugs for undruggable targets

Ternary Therapeutics is a preclinical-stage biotechnology company developing an AI-driven platform for the rational design of molecular glue therapeutics. Molecular glues are small molecules that induce proximity between two proteins, enabling targeted degradation or modulation of disease-driving targets that lack conventional drug-binding sites. The platform integrates machine learning, physics-based molecular modelling, and iterative experimental validation. Lead programmes are focused on inflammatory and neuroinflammatory diseases.

In silico software and AI for small molecule drug discovery

Optibrium is a software company providing integrated computational platforms for small molecule design, optimisation and data analysis across preclinical drug discovery. Its tools support compound property prediction, multi-parameter optimisation, AI-driven data analysis, de novo design, and structure-based modelling, enabling discovery teams to make more informed decisions at the hit-to-lead and lead optimisation stages. The company serves pharmaceutical, biotechnology and agrochemical organisations globally.

AI and quantum-chemical platform for small-molecule drug design

Tres Alchemix is the UK subsidiary of a Japanese biotechnology company developing an AI-driven drug-design platform for small-molecule therapeutics. The platform integrates quantum-level chemical calculations with AI models trained on biochemical and pharmacological datasets to predict the efficacy and safety of novel compounds in silico, enabling high-precision candidate design without early-stage physical screening. The company's initial therapeutic focus is oncology. Its UK research and development hub is based at The Oxford Science Park.

Generative AI platform for whole-organism biological modelling

AI Vivo is an early-stage Cambridge biotechnology company developing a generative AI system that constructs multi-scale biological models linking molecular targets through tissue and organ levels to whole-organism physiology. Its technology integrates multi-modal omics data to simulate disease dynamics and treatment responses, aiming to replace conventional cell-based and animal models in early drug discovery and pharmacology.

AI platform for pharma drug discovery workflows

DaltonTx is a technology company building adaptive AI-enabled discovery platforms for the pharmaceutical industry. Its disease- and modality-agnostic platform integrates into pharma, biotech and CRO workflows, supporting both small molecule and biologics discovery through a self-learning system that improves with every experiment. The platform powers the full discovery process from data integration and model training to molecular design and decision-making.

Integrated contract drug discovery from Cambridge and India

o2h is a contract research organisation operating an integrated drug discovery platform from Cambridge, UK, and Ahmedabad, India. Core services span medicinal chemistry, biology, DMPK, and non-GMP scale-up, supporting hit-to-lead optimisation through to IND-enabling studies. The company works across small molecule, PROTAC, peptide, and fragment-based modalities. The broader o2h group encompasses venture investment, a proprietary therapeutics pipeline, co-working laboratory space, and a technology arm.